Kukje Pharma Co Ltd (KO:002720) — Market Cap & Net Worth
Market Cap & Net Worth: Kukje Pharma Co Ltd (002720)
Kukje Pharma Co Ltd (KO:002720) has a market capitalization of $49.13 Million (₩72.49 Billion) as of June 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #22026 globally and #1354 in its home market, demonstrating a 11.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kukje Pharma Co Ltd's stock price ₩3560.00 by its total outstanding shares 20362502 (20.36 Million). Review Kukje Pharma Co Ltd debt and liabilities to assess the company's total debt and financial obligations.
Kukje Pharma Co Ltd Market Cap History: 2015 to 2026
Kukje Pharma Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $40.21 Million to $49.13 Million (0.09% CAGR).
Kukje Pharma Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kukje Pharma Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Kukje Pharma Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Kukje Pharma Co Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $40.21 Million | $117.64 Billion | -$5.94 Billion | 0.00x | N/A |
| 2016 | $51.27 Million | $120.68 Billion | $773.06 Million | 0.00x | 0.07x |
| 2017 | $61.14 Million | $123.31 Billion | $1.09 Billion | 0.00x | 0.06x |
| 2018 | $50.90 Million | $107.68 Billion | $2.19 Billion | 0.00x | 0.02x |
| 2019 | $55.19 Million | $111.12 Billion | -$4.76 Billion | 0.00x | N/A |
| 2020 | $120.40 Million | $130.39 Billion | $2.20 Billion | 0.00x | 0.05x |
| 2021 | $76.85 Million | $119.75 Billion | -$1.56 Billion | 0.00x | N/A |
| 2022 | $72.28 Million | $126.58 Billion | $3.56 Billion | 0.00x | 0.02x |
| 2023 | $81.69 Million | $135.37 Billion | -$8.42 Billion | 0.00x | N/A |
| 2024 | $69.82 Million | $156.46 Billion | $5.21 Billion | 0.00x | 0.01x |
Competitor Companies of 002720 by Market Capitalization
Companies near Kukje Pharma Co Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to Kukje Pharma Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Kukje Pharma Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Kukje Pharma Co Ltd's market cap moved from $40.21 Million to $ 49.13 Million, with a yearly change of 0.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩49.13 Million | -17.21% |
| 2025 | ₩59.34 Million | -15.02% |
| 2024 | ₩69.82 Million | -14.53% |
| 2023 | ₩81.69 Million | +13.02% |
| 2022 | ₩72.28 Million | -5.94% |
| 2021 | ₩76.85 Million | -36.17% |
| 2020 | ₩120.40 Million | +118.14% |
| 2019 | ₩55.19 Million | +8.43% |
| 2018 | ₩50.90 Million | -16.75% |
| 2017 | ₩61.14 Million | +19.25% |
| 2016 | ₩51.27 Million | +27.52% |
| 2015 | ₩40.21 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Kukje Pharma Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.13 Million USD |
| MoneyControl | $49.13 Million USD |
| MarketWatch | $49.13 Million USD |
| marketcap.company | $49.13 Million USD |
| Reuters | $49.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kukje Pharma Co Ltd
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other a… Read more